Cargando…

High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Miyamoto, M, Takano, M, Iwaya, K, Shinomiya, N, Goto, T, Kato, M, Suzuki, A, Aoyama, T, Hitrata, J, Nagaoka, I, Tsuda, H, Furuya, K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355918/ https://www.ncbi.nlm.nih.gov/pubmed/27832666 http://dx.doi.org/10.1038/bjc.2016.371

Ejemplares similares

High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers
por: Miyamoto, M, et al.
Publicado: (2015)

X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary
por: Miyamoto, M, et al.
Publicado: (2014)

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer
por: Koti, M, et al.
Publicado: (2015)

BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress
por: Cesaratto, Laura, et al.
Publicado: (2016)

Prognostic relevance of high pretreatment CA125 levels in primary serous ovarian cancer
por: Bachmann, Robert, et al.
Publicado: (2021)

Comparison of clinical behavior between mucinous ovarian carcinoma with infiltrative and expansile invasion and high-grade serous ovarian carcinoma: a retrospective analysis
por: Hada, Taira, et al.
Publicado: (2022)

Clinical significance of CD8‐positive lymphocytes on tumor cell clusters of ascites cell block in ovarian high‐grade serous carcinoma
por: Iwahashi, Hideki, et al.
Publicado: (2022)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer
por: Vanguri, Rami, et al.
Publicado: (2022)

Corrigendum to: Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population‐based testing program
Publicado: (2021)

Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018)

Why the dual origins of high grade serous ovarian cancer matter
por: Colvin, Emily K., et al.
Publicado: (2020)

Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma
por: Marchocki, Zibi, et al.
Publicado: (2022)

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro
por: O'Brien, P M, et al.
Publicado: (2008)

Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer
por: Crispin-Ortuzar, Mireia, et al.
Publicado: (2023)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

High-grade serous ovarian cancer: the clone wars
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2017)

Molecular Management of High-Grade Serous Ovarian Carcinoma
por: Punzón-Jiménez, Paula, et al.
Publicado: (2022)

Spatially resolved transcriptomics of high-grade serous ovarian carcinoma
por: Stur, Elaine, et al.
Publicado: (2022)

Lipid Alterations in Early-Stage High-Grade Serous Ovarian Cancer
por: Iurova, M. V., et al.
Publicado: (2022)

Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer
por: Lee, Yong Jae, et al.
Publicado: (2022)

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer
por: Koti, M, et al.
Publicado: (2015)

Prognostic gene expression signature for high-grade serous ovarian cancer
por: Millstein, J., et al.
Publicado: (2020)

Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways
por: Cleton-Jansen, A-M, et al.
Publicado: (2009)

Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review
por: Miyamoto, Morikazu, et al.
Publicado: (2013)

Fallopian tube origin of supposed ovarian high‐grade serous carcinomas
por: Diniz, Patricia Martini, et al.
Publicado: (2011)

High-grade serous ovarian carcinoma organoids as models of chromosomal instability
por: Vias, Maria, et al.
Publicado: (2023)

The peritoneal tumour microenvironment of high-grade serous ovarian cancer
por: Leinster, D Andrew, et al.
Publicado: (2012)

High grade serous ovarian carcinomas originate in the fallopian tube
por: Labidi-Galy, S. Intidhar, et al.
Publicado: (2017)

Principles of dormancy evident in high-grade serous ovarian cancer
por: Shepherd, Trevor G., et al.
Publicado: (2022)

Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers
por: Azzalini, Eros, et al.
Publicado: (2023)

Elastography, a sensitive tool for the evaluation of neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma
por: XIE, MENG, et al.
Publicado: (2014)

A chemotherapy response classifier based on support vector machines for high-grade serous ovarian carcinoma
por: Sun, Chao-Yang, et al.
Publicado: (2015)

Targeting Microtubule-Associated Protein Tau in Chemotherapy-Resistant Models of High-Grade Serous Ovarian Carcinoma
por: Barbolina, Maria V.
Publicado: (2022)

High HOXA9 gene expression predicts response to chemotherapy and prognosis of high-grade serous ovarian cancer patients
por: Li, Xiao-fei, et al.
Publicado: (2022)

The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer
por: Yan, Shunfei, et al.
Publicado: (2017)

Discovery and validation of serum glycoprotein biomarkers for high grade serous ovarian cancer
por: Dutt, Mriga, et al.
Publicado: (2023)

Molecular Characterization of an Intact p53 Pathway Subtype in High-Grade Serous Ovarian Cancer
por: Hayano, Takahide, et al.
Publicado: (2014)

Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas
por: Miyamoto, Morikazu, et al.
Publicado: (2017)

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma
por: Norris, Eric J, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e627lc4bls87146fhudheiie61